Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) EPS (Diluted) : $-0.46 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings EPS (Diluted)?

Panacea Life Sciences Holdings's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.09. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.46.

Panacea Life Sciences Holdings's EPS (Basic) for the three months ended in Mar. 2024 was $-0.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.46.

Panacea Life Sciences Holdings's EPS without NRI for the three months ended in Mar. 2024 was $-0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.41.

During the past 3 years, the average EPS without NRIGrowth Rate was -11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Panacea Life Sciences Holdings's highest 3-Year average EPS without NRI Growth Rate was -11.60% per year. The lowest was -11.60% per year. And the median was -11.60% per year.

Panacea Life Sciences Holdings EPS (Diluted) Historical Data

The historical data trend for Panacea Life Sciences Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings EPS (Diluted) Chart

Panacea Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

-0.31

-0.28

-0.62

-0.48

Panacea Life Sciences Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial											-0.12	-0.11	-0.13	-0.13	-0.09

Competitive Comparison of Panacea Life Sciences Holdings's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's PE Ratio falls into.

Panacea Life Sciences Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Panacea Life Sciences Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.015	-	0)	/	16.627
	=	-0.48

Panacea Life Sciences Holdings's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.446	-	0)	/	16.493
	=	-0.09

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46

Panacea Life Sciences Holdings (OTCPK:PLSH) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Panacea Life Sciences Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121

Website

https://www.panacealife.com

Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.

Executives

Leslie Buttorff	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER	16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger	director	5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman	officer: CONTROLLER & PRIN ACTNG OFCR	16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc.	10 percent owner	8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner	10 percent owner	65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert	director	170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du	officer: Chief Growth Officer	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis	director	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky	director, 10 percent owner	332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz	director	332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson	officer: Chief Strategy Officer	80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi	officer: President	510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert	director, officer: Executive Chairman	36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price	director	4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval	director	NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019